JAK2 and nonpapillary renal cell carcinoma: Indeed, recent studies showed that human ccRCC cell lines were sensitive to Jak2-STAT pathway activity induced by dimethoxycurcumin [17], and recent clinical data suggested that the effects of drugs regularly used to treat RCC might elicit their anti-tumor effects via targeting of the STAT pathway.